The Ensign Group Inc (ENSG)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at The Ensign Group Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 177.20 $ — 44% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AAQS
7/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 13.2%
- Exp. sales growth 3Y > 5% 13.4%
- EBIT growth 10Y > 5% 18.6%
- Exp. EBIT growth 3Y > 5% 21.0%
- Net debt < 4x EBIT 8.4x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 53.0%
- Return on equity > 15% 16.2%
- ROCE > 15% 9.3%
- Expected return > 10% 25.3%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 18.7% passed
- More than 10% revenue growth is expected for the coming year 10.1% passed
- Share count grows by less than 3% a year 1.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 26.0% failed
- Gross margin at 40% or higher and without meaningful erosion 15.8% failed
- Goodwill from acquisitions does not grow faster than revenue 1.8% passed
- Net debt below twice EBITDA 6.3 x EBITDA failed
- Operating cash flow covers the profits of the last three years 437 m passed
- Return on capital at 15% or higher, or up versus two years ago 9.3% passed
- Insiders hold at least 10% or are net buyers 3.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 24.2% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7.79 | 7.73 – 7.82 | 5,905 | 18.6% | 5 |
| 12/31/2027 | 8.55 | 8.41 – 8.83 | 6,505 | 9.7% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.36 | 260.90 | 1,132 | 15.50 | 7.00 | 101 | 52 |
| 2025: Q1 | 1.37 | 15.50 | 1,173 | 16.10 | 6.80 | 72 | 29 |
| 2025: Q2 | 1.44 | 17.70 | 1,228 | 18.50 | 6.90 | 156 | 106 |
| 2025: Q3 | 1.42 | 6.00 | 1,296 | 19.80 | 6.50 | 153 | 102 |
| 2025: Q4 | 1.61 | 18.30 | 1,361 | 20.20 | 7.00 | 183 | 134 |
| 2026: Q1 | 1.67 | 21.90 | 1,389 | 18.40 | 7.20 | 100 | 65 |
| 2026: Q2 | 1.68 | 16.70 | 1,441 | 17.30 | 6.90 | 172 | 172 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,655 | 92 | 50 | 0.96 | 74 | 456 | 1,001 |
| 2017 | 1,598 | 43 | 40 | 0.77 | 73 | 492 | 1,102 |
| 2018 | 1,755 | 85 | 92 | 1.70 | 210 | 591 | 1,182 |
| 2019 | 2,037 | 129 | 111 | 1.97 | 169 | 654 | 2,362 |
| 2020 | 2,403 | 223 | 170 | 3.06 | 373 | 818 | 2,546 |
| 2021 | 2,627 | 260 | 195 | 3.42 | 276 | 1,021 | 2,851 |
| 2022 | 3,025 | 297 | 225 | 3.95 | 273 | 1,247 | 3,452 |
| 2023 | 3,729 | 255 | 209 | 3.65 | 377 | 1,492 | 4,178 |
| 2024 | 4,260 | 358 | 298 | 5.12 | 347 | 1,837 | 4,669 |
| 2025 | 5,058 | 425 | 344 | 5.84 | 564 | 2,232 | 5,463 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
The Ensign Group, Inc. bietet Dienste in den Bereichen Pflege, Seniorenwohnen und Rehabilitation an.
| Employees | 46,000 |
|---|---|
| Headquarters | San Juan Capistrano, CA |
| Address | 29222 Rancho Viejo Road, 92675 San Juan Capistrano, United States |
| Phone | 949 487 9500 |
| Website | ensigngroup.net |
| IPO Date | 9. Nov 2007 |
| ISIN | US29358P1012 |
| Stock Split | 1069:1000 on 10/01/2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Barry R. Port | CEO & Chairman of the Board | 1974 |
| Spencer W. Burton | President & COO | 1979 |
| Suzanne D. Snapper CPA | CFO, Executive VP & Director | 1974 |
| Chad A. Keetch J.D. | Chief Investment Officer, Executive VP & Secretary | 1978 |
| Beverly B. Wittekind | Executive VP & General Counsel | 1965 |
| Kevin Reese | President of Keystone Healthcare Inc | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Blouin Ann Scott | Director | Sell | 200 | 185.00 | 37,000 |
| 27. Jul 2026 | Blouin Ann Scott | Director | Sell | 175 | 181.88 | 31,829 |
| 20. Jul 2026 | Agwunobi John O | Director | Sell | 392 | 171.06 | 67,056 |
| 16. Jul 2026 | Parkinson Mark Vincent | Director | Sell | 100 | 168.12 | 16,812 |
| 15. Jul 2026 | Parkinson Mark Vincent | Director | Other | 600 | 0.00 | – |
| 15. Jul 2026 | Blouin Ann Scott | Director | Other | 600 | 0.00 | – |
| 15. Jul 2026 | Abbott Swati Bargotra | Director | Other | 600 | 0.00 | – |
| 15. Jul 2026 | Agwunobi John O | Director | Other | 600 | 0.00 | – |
| 15. Jul 2026 | Shaw Daren | Director | Other | 600 | 0.00 | – |
| 15. Jul 2026 | Smith Barry M | Director | Other | 600 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.